Ten years of experience of biologics in juvenile idiopathic arthritis: focus for the reasons of withdrawals

Methods The analysis includes data about 435 patients with JIA who have been getting Biologics in 2005 2014. The average age of patients is 10,5 years (from 1,5 to 18 years). Disease duration is 7 yrs avg (from 3 to 14 years). Clinical characteristics: soJIA 70 (17%), JIA with polyarthicular course (poly) 257 (61%), JIA oligo – 38 (9%), 51 (12%) patients suffered from active uveitis. Results During the observation Biologics were withdrawn in 123 cases (98 patients). For some patient we changed Biologics several times: in 21 cases two times (21% of patients), in 2 cases (2%) thrice. Distribution of reasons for the Biologics discontinuation is presented in Table 1 below: Infliximab was withdrawn more often due to adverse events (infusion reactions), at the beginning of the treatment or several years later. The other reason is secondary inefficiency after 2-5 years of application. Abatacept was cancelled more often for the reason of inefficiency, adverse events were observed rarely. Etanercept was withdrawn in some cases because of uveitis de novo. Adalimumab was withdrawn basically due to organization problem. Favorable choice of Biologics is changed from 2005 till now. For new initiation we used different biologics in different time. Infliximab was administered in the past